Jason Rhodes Sells 272,049 Shares of Dyne Therapeutics (NASDAQ:DYN) Stock

Dyne Therapeutics, Inc. (NASDAQ:DYN) Director Jason Rhodes sold 272,049 shares of the stock in a transaction on Monday, April 20th. The shares were sold at an average price of $20.06, for a total value of $5,457,302.94. Following the sale, the director directly owned 14,561 shares in the company, valued at $292,093.66. This trade represents a 94.92% decrease in their position. The sale was disclosed in a filing with the SEC, which is accessible through the SEC website. The transaction was executed under a pre-arranged Rule 10b5-1 trading plan.

Dyne Therapeutics Trading Down 3.9%

DYN opened at $18.90 on Friday. The company has a current ratio of 22.25, a quick ratio of 22.25 and a debt-to-equity ratio of 0.15. The firm has a market cap of $3.12 billion, a price-to-earnings ratio of -5.34 and a beta of 1.29. Dyne Therapeutics, Inc. has a 12 month low of $8.06 and a 12 month high of $25.00. The stock has a fifty day moving average price of $17.64 and a 200-day moving average price of $18.37.

Dyne Therapeutics (NASDAQ:DYN) last issued its quarterly earnings data on Monday, March 2nd. The company reported ($0.76) earnings per share for the quarter, missing analysts’ consensus estimates of ($0.74) by ($0.02). As a group, equities research analysts anticipate that Dyne Therapeutics, Inc. will post -2.94 earnings per share for the current fiscal year.

Hedge Funds Weigh In On Dyne Therapeutics

Several hedge funds and other institutional investors have recently modified their holdings of DYN. Hilton Head Capital Partners LLC acquired a new stake in Dyne Therapeutics in the 1st quarter worth approximately $26,000. Chung Wu Investment Group LLC acquired a new position in Dyne Therapeutics during the 3rd quarter valued at approximately $30,000. Strs Ohio purchased a new position in shares of Dyne Therapeutics in the fourth quarter worth $51,000. Mirae Asset Global Investments Co. Ltd. raised its holdings in shares of Dyne Therapeutics by 25.3% in the third quarter. Mirae Asset Global Investments Co. Ltd. now owns 5,500 shares of the company’s stock worth $70,000 after buying an additional 1,109 shares during the last quarter. Finally, Aster Capital Management DIFC Ltd acquired a new stake in shares of Dyne Therapeutics during the fourth quarter worth $84,000. 96.68% of the stock is owned by hedge funds and other institutional investors.

Analyst Ratings Changes

DYN has been the topic of a number of analyst reports. Wall Street Zen downgraded shares of Dyne Therapeutics from a “hold” rating to a “sell” rating in a research report on Sunday, December 28th. Jefferies Financial Group restated a “buy” rating on shares of Dyne Therapeutics in a research note on Monday, March 9th. HC Wainwright cut their price target on shares of Dyne Therapeutics from $60.00 to $50.00 and set a “buy” rating on the stock in a report on Tuesday, March 3rd. Weiss Ratings reaffirmed a “sell (d-)” rating on shares of Dyne Therapeutics in a research report on Monday. Finally, Chardan Capital reiterated a “buy” rating and set a $38.00 price objective on shares of Dyne Therapeutics in a report on Monday, March 9th. Three research analysts have rated the stock with a Strong Buy rating, eleven have issued a Buy rating, two have given a Hold rating and one has given a Sell rating to the company’s stock. According to data from MarketBeat, the company currently has a consensus rating of “Moderate Buy” and a consensus target price of $35.14.

About Dyne Therapeutics

Dyne Therapeutics is a clinical-stage biotechnology company specializing in the development of localized gene regulation therapies for serious rare diseases. The company’s proprietary FORCE (Facilitated Orthogonal Receptor‐mediated Cargo Evaluation) platform is designed to enable targeted delivery of oligonucleotide and gene therapy modalities to skeletal and respiratory muscles. Dyne’s lead programs focus on Duchenne muscular dystrophy (DMD), myotonic dystrophy type 1 (DM1) and facioscapulohumeral muscular dystrophy (FSHD), with preclinical and early clinical studies evaluating safety, tolerability and tissue specificity.

Since its founding in 2019 by Flagship Pioneering, Dyne has advanced multiple product candidates using its modular delivery approach, which couples engineered ligands with therapeutic payloads to improve uptake into muscle cells.